19 . January , 2019 - Saturday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Pamidronate Disodium

Big Image Pronouncation: (pam-IH-DROE-nate die-SO-dee-uhm)
Class: Bisphosphonate

Trade Names:
Aredia
- Powder for injection, lyophilized 30 mg
- Powder for injection, lyophilized 90 mg

Trade Names:
Pamidronate Disodium
- Injection 3 mg/mL
- Injection 6 mg/mL
- Injection 9 mg/mL

Mechanism of Action

Pharmacology

Inhibits normal and abnormal bone resorption.

Pharmacokinetics

Distribution

Adsorbed to bone in areas of high turnover.

Metabolism

Not metabolized.

Elimination

Renal excretion (46% unchanged). The t ½ is 28 hr. Renal Cl is 49 mL/min.

Indications and Usage

Treatment of moderate to severe hypercalcemia associated with malignancy with or without bone metastases; treatment of moderate to severe Paget disease of bone; treatment of osteolytic bone lesions of multiple myeloma and bone metastases of breast cancer in conjunction with standard chemotherapy.

Unlabeled Uses

Treatment of postmenopausal osteoporosis; treatment of hyperparathyroidism; prevention of glucocorticoid-induced osteoporosis; management of immobilization-related hypercalcemia; reduction of bone pain in prostatic carcinoma.

Contraindications

Hypersensitivity to bisphosphonates.

Dosage and Administration

Moderate to Severe Hypercalcemia of Malignancy
Adults

IV For moderate, give 60 to 90 mg as an initial single-dose infusion over 2 to 24 hr. For severe, give 90 mg as an initial single-dose infusion over 2 to 24 hr. For retreatment, same as initial therapy, at least 7 days after initial dose.

Paget Disease
Adults

IV 30 mg/day as a 4-hr infusion on 3 consecutive days for a total dose of 90 mg. For retreatment, same as initial therapy, when clinically indicated.

Osteolytic Bone Metastases of Breast Cancer
Adults

IV 90 mg as a 2-hr infusion q 3 to 4 wk.

Osteolytic Bone Lesions of Multiple Myeloma
Adults

IV 90 mg as a 4-hr infusion on a monthly basis.

General Advice

  • For IV administration only. Not for intradermal, subcutaneous, IM, intra-arterial, or oral administration.
  • Concentrated injection solution must be further diluted before administration.
  • Reconstitute lyophilized powder with 10 mL sterile water for injection. Allow drug to dissolve completely before withdrawing for further dilution.
  • Do not administer if particulate matter or discoloration noted.
  • Administer diluted solution via separate IV line.
Hypercalcemia of malignancy
  • Dilute the recommended dose in 1,000 mL 0.45% or 0.9% sodium chloride or 5% dextrose injection. Infuse prescribed dose over 2 to 24 hr as ordered.
Paget disease
  • Dilute the recommended dose in 500 mL 0.45% or 0.9% sodium chloride or 5% dextrose injection. Infuse prescribed dose over 4 hr.
Osteolytic bone lesions of multiple myeloma
  • Dilute the recommended dose in 500 mL 0.45% or 0.9% sodium chloride or 5% dextrose injection. Infuse prescribed dose over 4 hr.
Osteolytic bone metastases of breast cancer
  • Dilute the recommended dose in 500 mL 0.45% or 0.9% sodium chloride or 5% dextrose injection. Infuse prescribed dose over 2 hr.

Storage/Stability

Store unopened vials below 86°F. Powder reconstituted with sterile water for injection may be stored in refrigerator (36° to 46°F) for up to 24 hr. Diluted solution for infusion may be stored at room temperature for up to 24 hr.

Drug Interactions

None well documented.

Incompatibility

Calcium-containing infusion solutions (eg, Ringer's solution). Do not mix.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Cardiovascular

Atrial fibrillation; atrial flutter; cardiac failure; hypertension; syncope; tachycardia.

CNS

Asthenia; anxiety; fatigue; headache; insomnia; paresthesia; psychosis; somnolence.

Dermatologic

Sweating.

Endocrine

Hypothyroidism.

GI

Abdominal pain; anorexia; constipation; diarrhea; dyspepsia; GI hemorrhage; nausea; stomatitis; vomiting.

Genitourinary

UTI; uremia; renal toxicity.

Hematologic-Lymphatic

Anemia; granulocytopenia; leukopenia; neutropenia; thrombocytopenia.

Lab Tests

Hypocalcemia; hypokalemia; hypomagnesemia; hypophosphatemia.

Local

Infusion-site reaction.

Musculoskeletal

Arthralgia; arthrosis; back pain; bone pain; musculoskeletal pain; myalgia; osteonecrosis primarily of the jaws (postmarketing).

Respiratory

Coughing; dyspnea; pleural effusion; rales; rhinitis; sinusitis; upper respiratory infection.

Miscellaneous

Edema; fever; metastases; moniliasis; pain; allergic manifestations (eg, hypotension, dyspnea, angioedema, anaphylactic shock) (postmarketing).

Precautions

Monitor

Baseline tests

Assess CBC, differential, hemoglobin, and hematocrit before therapy is initiated. Monitor these parameters closely for the first 2 wk of therapy if preexisting anemia, leukopenia, or thrombocytopenia is noted. Assess serum calcium, phosphate, magnesium, and potassium before and periodically during therapy.


Pregnancy

Category D .

Lactation

Undetermined.

Children

Safety and efficacy not established.

Hypocalcemia

Hypocalcemia has occurred.

GI disorders

Use with caution in patients with active upper GI problems such as dysphagia (eg, difficulty swallowing), symptomatic esophageal diseases, gastritis, duodenitis, or ulcers.

Osteonecrosis of the jaw

Has been reported in patients with cancer receiving treatment regimens that include bisphosphonates. Risk factors include cancer chemotherapy, corticosteroid administration, and poor oral hygiene. Ensure that a dental examination is performed, and preventive dentistry is completed, before starting therapy in patient at risk for developing osteonecrosis of the jaw (eg, cancer, chemotherapy, corticosteroids, poor oral hygiene). While on treatment, avoid invasive dental procedures if possible.

Renal insufficiency

Because pamidronate is excreted primarily by the kidney, the risk of adverse reactions may be increased in patients with impaired renal function. In patients receiving pamidronate for bone metastases and who have evidence of renal function deterioration, the drug should be withheld until renal function returns to baseline. Pamidronate has not been tested in patients with class Dc renal impairment (creatinine above 5 mg/dL). Ensure that serum creatinine is assessed before each dose of pamidronate.

Overdosage

Symptoms

High fever, hypotension, hypocalcemia, transient taste perversion.

Patient Information

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient that medication will be prepared and administered by a health care provider in a health care setting and that medication will not be administered at home.
  • Advise patient that infusion-site reactions (eg, redness, swelling, hardness, pain) can be treated with local measures (eg, warm or cold packs) and oral OTC analgesics (eg, acetaminophen, ibuprofen). Advise patient to report infusion-site reactions that do not respond to symptomatic treatment to health care provider.
  • Instruct patient to report the following symptoms to health care provider: tingling, numbness, muscle spasms, stomach pain, fever, fatigue, swelling, nausea, appetite loss, constipation, diarrhea, vomiting, inflammation of the mouth, difficulty breathing, muscle or bone pain.
  • Advise women of childbearing potential to use effective contraception during treatment with pamidronate.
  • Advise women to notify health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient not to take any prescription or OTC medications, herbal preparations, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and laboratory tests will be required to monitor therapy and to keep appointments.

Recent Drug Updates at DrugIndexOnline:





Acetohexamide Acetohexamide
Some commonly used brand names are: In the U.S.— Amaryl 4 DiaBeta 6 Diabinese 2 Dymelor 1 Glucotrol 5 Glucotrol XL 5 Glynase PresTab 6 Micronase 6 Orinase 8 Tolinase 7 In Canada— Albert Glyburide 6 Apo-Chlorpropamide 2 Apo-Glyburide 6 Apo-Tolbutamide 8 DiaBeta 6 Diabinese 2 Diamic more...

Crixivan Crixivan
Some commonly used brand names are: In the U.S.— Crixivan In Canada— Crixivan Category Antiviral, systemic Description Indinavir (in-DIN-a-veer) is used, alone or in combination with other medicines, in the treatment of the infection caused by the human immunodeficiency v more...

Depo-Provera Depo-Provera
Generic name: Medroxyprogesterone acetate Brand names: Depo-Provera Why is Depo-Provera prescribed? Depo-Provera Contraceptive Injection is given in the buttock or upper arm to prevent pregnancy. It is more than 99 percent effective; your chances of becoming pregnant during the first year of use more...

Entocort EC Entocort EC
Generic name: Brand names: Entocort EC Why is Entocort EC prescribed? Entocort EC is used to treat Crohn's disease, a chronic intestinal inflammation that causes sustained diarrhea and abdominal pain. The drug contains the anti-inflammatory steroid budesonide in a special formulation that conce more...

Folic Acid Folic Acid
Pronouncation: (FOE-lik AH-sid) Class: Vitamin Trade Names: Folic Acid - Tablets 0.4 mg - Tablets 0.8 mg - Tablets 1 mg Trade Names: Folvite - Tablets 1 mg - Injection 5 mg/mL Apo-Folic (Canada) Mechanism of Action Pharmacology Required for nucleoprotein synthesis and maintenance of normal erythrop more...

Gentamicin Ophthalmic Ointment Gentamicin Ophthalmic Ointment
Generic Name: Gentamicin sulfate Dosage Form: Ophthalmic ointment Rx only DESCRIPTION: Gentamicin sulfate is a water soluble antibiotic of the aminoglycoside group. Gentamicin Sulfate Ophthalmic Ointment USP is a sterile ointment for topical ophthalmic use. Each gram contains Gentamicin sulfate more...

Lariam Lariam
Some commonly used brand names are: In the U.S.— Lariam In Canada— Lariam Category Antimalarial Description Mefloquine (ME-floe-kwin) belongs to a group of medicines called antimalarials. It is used to prevent or treat malaria, a red blood cell infection transmitted by th more...

Nizatidine Nizatidine
Pronouncation: (nye-ZA-ti-deen) Class: Histamine H 2 antagonist Trade Names: Axid - Solution, oral 15 mg/mL Trade Names: Axid AR - Tablets 75 mg Trade Names: Axid Pulvules - Capsules 150 mg - Capsules 300 mg Apo-Nizatidine (Canada) Novo-Nizatidine (Canada) PMS-Nizatidine (Canada) Mechanism of Actio more...